Phase 2 Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older at the time of signing the consent form
- People who have a confirmed diagnosis of sickle cell disease (SCD), of any type
- People who have had between 1 and 12 pain crises in the past 12 months that required a visit to a medical facility and treatment with pain relief given by injection or IV
- People who have been on a stable, well-tolerated dose of a medicine called Hydroxyurea for at least 30 days before the screening visit, OR people who stopped taking or chose not to take Hydroxyurea (for example, due to side effects or because it was not working)
Who may not be able to join:
- People whose blood test at screening or at the first study visit shows a low level of a type of white blood cell called neutrophils (below a specific threshold — confirm with trial site)
- People who are taking a preventive medication for sickle cell disease but whose dose has changed in the 30 days before the screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, CSL Behring
Phone: +1 610-878-4697
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with Treatment Emergent Adverse Events (TEAEs), Overall and by severity, seriousness and relationship to Investigational Product (IP); Percentage of participants with TEAEs Overall and by severity, seriousness and relationship to IP; Number of participants with Adverse Events of Special Interest (AESI); Percentage of participants with AESI; Number of participants with clinically relevant changes from baseline in laboratory assessments and vital signs; Percentage of participants with clinically relevant changes from baseline in laboratory assessments and vital signs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.